<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Int Med Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Int. Med. Res</journal-id>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title-group>
<journal-title>The Journal of International Medical Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32696690</article-id>
<article-id pub-id-type="pmc">7376300</article-id>
<article-id pub-id-type="doi">10.1177/0300060519884856</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060519884856</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Exploring concomitant neuroimaging and genetic alterations in
patients with and patients without auditory verbal hallucinations: A pilot study
and mini review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Haiping</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300060519884856">1</xref>
<xref ref-type="author-notes" rid="fn1-0300060519884856">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ying</surname>
<given-names>Wang</given-names>
</name>
<xref ref-type="aff" rid="aff2-0300060519884856">2</xref>
<xref ref-type="author-notes" rid="fn1-0300060519884856">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Gang</given-names>
</name>
<xref ref-type="aff" rid="aff3-0300060519884856">3</xref>
<xref ref-type="author-notes" rid="fn1-0300060519884856">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Xiaodong</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300060519884856">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Deguo</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300060519884856">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Guangdong</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300060519884856">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Suling</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300060519884856">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Xiuhai</given-names>
</name>
<xref ref-type="aff" rid="aff4-0300060519884856">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Yong</given-names>
</name>
<xref ref-type="aff" rid="aff5-0300060519884856">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ye</surname>
<given-names>Jiaen</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300060519884856">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-3793-550X</contrib-id>
<name>
<surname>Zhuo</surname>
<given-names>Chuanjun</given-names>
</name>
<xref ref-type="aff" rid="aff1-0300060519884856">1</xref>
<xref ref-type="aff" rid="aff2-0300060519884856">2</xref>
<xref ref-type="aff" rid="aff6-0300060519884856">6</xref>
<xref ref-type="aff" rid="aff7-0300060519884856">7</xref>
<xref ref-type="corresp" rid="corresp1-0300060519884856"></xref>
</contrib>
<aff id="aff1-0300060519884856">
<label>1</label>Department of Psychiatric-Neuro-Imaging-Genetics Laboratory,
Wenzhou Seventh People’s Hospital, Wenzhou, Zhejiang, China</aff>
<aff id="aff2-0300060519884856">
<label>2</label>Psychiatric Neuroimaging–Genetic and Comorbidity Laboratory,
Tianjin Mental Health Centre, Tianjin Anding Hospital, Tianjin, China</aff>
<aff id="aff3-0300060519884856">
<label>3</label>Department of Psychiatry, Tianshui Third Hospital, Gansu,
China</aff>
<aff id="aff4-0300060519884856">
<label>4</label>Department of Neurology, Zoucheng People’s Hospital, Jining
Medical University Affiliated Zoucheng Hospital, Shandong, China</aff>
<aff id="aff5-0300060519884856">
<label>5</label>Department of Psychiatry, The First Hospital of Shanxi Medical
University, Shanxi, China</aff>
<aff id="aff6-0300060519884856">
<label>6</label>Department of Psychiatry, Tianjin Fourth Centre Hospital,
Tianjin, China</aff>
<aff id="aff7-0300060519884856">
<label>7</label>Department of Psychiatric-Neuro-Imaging-Genetics Laboratory,
School of Mental Health of Jining Medical University, Jining, Shandong,
China</aff>
</contrib-group>
<author-notes>
<fn fn-type="equal" id="fn1-0300060519884856">
<label>*</label>
<p>These authors contributed equally to this work.</p>
</fn>
<corresp id="corresp1-0300060519884856">Chuanjun Zhuo, Room A320, Institute of Key
Laboratory of Psychiatry, 1 Zhongshan Road, Hebei District, Tianjin Fourth
Centre Hospital, 300024, Tianjin, China. Emails:
<email>chuanjunzhuotjmh@163.com</email>;
<email>chuanjunzhuotjmh@ieee.org</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>7</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>7</month>
<year>2020</year>
</pub-date>
<volume>48</volume>
<issue>7</issue>
<elocation-id>0300060519884856</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
<license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
<license-p>Creative Commons Non Commercial CC BY-NC: This article is distributed
under the terms of the Creative Commons Attribution-NonCommercial 4.0
License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>To explore concomitant neuroimaging and genetic alterations in patients with
schizophrenia with or without auditory verbal hallucinations (AVHs), and to
discuss the use of pattern recognition techniques in the development of an
objective index that may improve diagnostic accuracy and treatment outcomes
for schizophrenia.</p>
</sec>
<sec>
<title>Methods</title>
<p>The pilot study included patients with schizophrenia with AVHs (SCH-AVH
group) and without AVHs (SCH-no AVH group). High throughput sequencing (HTS)
was performed to explore RNA networks. Global functional connectivity
density (gFCD) analysis was performed to assess functional connectivity (FC)
alterations of the default mode network (DMN). Quantitative long noncoding
(lnc) RNA and mRNA expression data were related to peak T values of gFCDs
using Pearson’s correlation coefficient analysis.</p>
</sec>
<sec>
<title>Results</title>
<p>Compared with the SCH-no AVH group (<italic>n</italic> = 5), patients in the
SCH-AVH group (<italic>n</italic> = 5) exhibited differences in RNA
expression in RNA networks that were related to AVH severity, and displayed
alterations in FC (reflected by gFCD differences) within the DMN (posterior
cingulate and dorsal-medial prefrontal cortex), and in the right parietal
lobe, left occipital lobe, and left temporal lobe. Peak lncRNA expression
values were significantly related to peak gFCD T values within the DMN.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Among patients with schizophrenia, there are concomitant FC and genetic
expression alterations associated with AVHs. Data from pattern recognition
studies may inform the development of an objective index aimed at improving
early diagnostic accuracy and treatment planning for patients with
schizophrenia with and without AVHs.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Auditory verbal hallucinations</kwd>
<kwd>neuroimaging–genetics</kwd>
<kwd>pattern recognition</kwd>
<kwd>predictive model</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>typesetter</meta-name>
<meta-value>ts2</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060519884856" sec-type="intro">
<title>Introduction</title>
<p>Auditory verbal hallucinations (AVHs) are experienced by people with a wide range of
mental disorders, including schizophrenia, bipolar disorder, major depressive
disorder, post-traumatic stress disorder, and borderline personality disorder.<sup><xref ref-type="bibr" rid="bibr1-0300060519884856">1</xref></sup> Individuals without any diagnosable neuropsychiatric disorder can also
experience AVHs.<sup><xref ref-type="bibr" rid="bibr2-0300060519884856">2</xref></sup> Due to their heterogeneity, people with AVHs are at risk of misdiagnoses and
improper treatment planning.</p>
<p>Because AVHs can be caused by a serious neurological problem, the International
Consortium on Hallucination Research (ICHR) included the phenomenon in its top 10
list of hot future research topics in the field of auditory hallucinations in
2013,<sup><xref ref-type="bibr" rid="bibr3-0300060519884856">3</xref>,<xref ref-type="bibr" rid="bibr4-0300060519884856">4</xref></sup> thereby
stimulating multi-dimensional studies of auditory hallucinations. In 2015, the ICHR
re-emphasized the need for multi-perspective and interdisciplinary auditory
hallucination research.<sup><xref ref-type="bibr" rid="bibr5-0300060519884856">5</xref></sup> Within the next couple of years, phenomenological and non-trend analysis
research demonstrated brain functional connectivity (FC) changes in patients with
schizophrenia who experience AVHs following commencement of clozapine treatment.<sup><xref ref-type="bibr" rid="bibr6-0300060519884856">6</xref></sup> Meanwhile, the application of linear support vector machines to functional
magnetic resonance imaging (fMRI) data has enabled researchers to commence
delineating AVH characteristics, including white matter connectivity alterations, in
patients with schizophrenia, and neuroimaging studies of AVHs have since expanded
rapidly worldwide.<sup><xref ref-type="bibr" rid="bibr6-0300060519884856">6</xref><xref ref-type="bibr" rid="bibr7-0300060519884856"></xref>–<xref ref-type="bibr" rid="bibr8-0300060519884856">8</xref></sup></p>
<p>Beyond neuroimaging, the ICHR has emphasized the importance of studying the
neuropathological characteristics of AVHs from multiple perspectives in different
populations. At the 2018 annual ICHR meeting, it was proposed that the pathological
characteristics of and potential treatments for AVHs should be explored at
molecular, synaptic, and neurotransmitter levels.<sup><xref ref-type="bibr" rid="bibr6-0300060519884856">6</xref></sup> Accordingly, the pursuits of ‘Understanding AVHs in healthy and psychotic
individuals: Features, imaging, and interventions’ (see <xref ref-type="fig" rid="fig1-0300060519884856">Figure 1</xref>),<sup><xref ref-type="bibr" rid="bibr9-0300060519884856">9</xref></sup> and ‘Auditory verbal hallucinations and the auditory network: from molecules
to connectivity’ (see <xref ref-type="fig" rid="fig2-0300060519884856">Figure
2</xref>),<sup><xref ref-type="bibr" rid="bibr10-0300060519884856">10</xref></sup> have emerged as urgent problems to be solved going forward. Empirical
clarification of pathological AVH subtypes may help prevent misdiagnosis and
improper treatment planning in patients with AVHs, and thus, ultimately, may help
clinicians to target treatment according to AVH subtype.<sup><xref ref-type="bibr" rid="bibr3-0300060519884856">3</xref><xref ref-type="bibr" rid="bibr4-0300060519884856"></xref><xref ref-type="bibr" rid="bibr5-0300060519884856"></xref><xref ref-type="bibr" rid="bibr6-0300060519884856"></xref><xref ref-type="bibr" rid="bibr7-0300060519884856"></xref>–<xref ref-type="bibr" rid="bibr8-0300060519884856">8</xref></sup></p>
<fig id="fig1-0300060519884856" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>Understanding auditory verbal hallucinations (AVHs) in healthy individuals
and patients with psychosis: features, imaging, and interventions (from Zhou
et al., 2019).<sup><xref ref-type="bibr" rid="bibr9-0300060519884856">9</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_0300060519884856-fig1"></graphic>
</fig>
<fig id="fig2-0300060519884856" orientation="portrait" position="float">
<label>Figure 2.</label>
<caption>
<p>Auditory verbal hallucinations (AVHs) and the auditory network: from
molecules to connectivity (from Huang et al., 2019).<sup><xref ref-type="bibr" rid="bibr10-0300060519884856">10</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_0300060519884856-fig2"></graphic>
</fig>
<p>The aim of the present pilot study was to explore concomitant neuroimaging and
genetic expression alterations in a small sample of patients with schizophrenia, and
to identify the alterations that differ between patients with versus those without
AVHs. Specifically, global FC density (gFCD) analyses were conducted to identify
patterns of FC alterations, particularly regarding the default mode network (DMN);
and high-throughput sequencing (HTS) technology was adopted with weighted gene
co-expression network analysis (WGCNA) and canonical correlation analysis (CCA) to
identify group-related mRNA network distinctions. A discussion is provided regarding
how neuroimaging, genetics, and-pattern recognition techniques may be employed to
explore specific neuroimaging-marker and genetic features of AVH subtype with the
goal of developing a potential objective index based on such features that can,
firstly, aid the clinical diagnosis of AVHs by subtype in an early stage and,
ultimately, support tailored treatment planning and the formulation of prognoses
according to AVH subtype.</p>
</sec>
<sec id="sec2-0300060519884856">
<title>Patients and methods</title>
<sec id="sec3-0300060519884856">
<title>Study population</title>
<p>This pilot study included two groups of patients who were recruited from the
inpatient population at Tianjin Anding Hospital, Tianjin, China between July
2017 and August 2017: patients with schizophrenia with AVHs (SCH-AVH group) and
patients with schizophrenia without AVHs (SCH-no AVH group). To minimize
potential confounding influences on aberrant brain or genetic features, efforts
were made to match these two groups with respect to sociodemographic
characteristics (age, sex ratio, and educational level), schizophrenia symptom
severity assessed by the Positive and Negative Syndrome Scale (PANSS),<sup><xref ref-type="bibr" rid="bibr11-0300060519884856">11</xref></sup> and antipsychotic agent dosages (reported as chlorpromazine equivalent dosages).<sup><xref ref-type="bibr" rid="bibr12-0300060519884856">12</xref></sup> The inclusion criteria were: (1) fully meeting criteria for schizophrenia
according to the American Psychiatric Association’s Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV, 1994); (2) unambiguous determination of
having or not having AVHs, as defined by the auditory hallucination rating scale (AHRS);<sup><xref ref-type="bibr" rid="bibr13-0300060519884856">13</xref></sup> (3) being 18–35 years of age; (4) having an intelligence quotient ≥80;
and (5) no substance misuse problems. The exclusion criteria were: (1) moderate
or severe physical disease (e.g. liver or kidney disease, or diseases of the
respiratory, cardiovascular, endocrine, or nervous system); (2) current
recipient of electroconvulsive therapy; (3) a history of loss of consciousness
for ≥5 min; (4) left-handedness (determined by the Annett Hand Preference Questionnaire),<sup><xref ref-type="bibr" rid="bibr14-0300060519884856">14</xref></sup> and (5) any fMRI contraindication. The pilot study was approved by the
Ethics Committee of Tianjin Anding Hospital and all study participants provided
written informed consent.</p>
</sec>
<sec id="sec4-0300060519884856">
<title>Acquisition of fMRI data</title>
<p>Images were acquired with a 3T GE Discovery MR750 scanner (General Electric,
Milwaukee, WI, USA) equipped with an eight-channel phased-array head coil. For
SCH-AVH participants, all images were captured during an AVH episode. During
scanning sessions, participants were required to remain still while lying in the
supine position without falling asleep. Whole-brain resting-state fMRI data
based on blood oxygen level-dependent signals were obtained with a gradient-echo
echo-planar imaging sequence with the following acquisition parameters:
repetition time (TR) = 2 000 ms; echo time (TE) = 45 ms; slices = 32; slice
thickness = 4 mm; gap =0.5 mm; field-of-view (FOV) = 220 × 220; matrix
size = 64 × 64; and flip angle (FA) =90°. Parallel imaging using the sensitivity
encoding technique (factor 2) was used to acquire all images. Structural images
were obtained with a high-resolution 3D Turbo-Fast Echo T1WI sequence with the
following parameters: 188 slices, TR/TE = 8.2/3.2, slice thickness = 1 mm, no
gap, FA = 12°, matrix size = 256 × 256, FOV = 256 × 256.<sup><xref ref-type="bibr" rid="bibr15-0300060519884856">15</xref>,<xref ref-type="bibr" rid="bibr16-0300060519884856">16</xref></sup></p>
</sec>
<sec id="sec5-0300060519884856">
<title>Data preprocessing</title>
<p>Resting-state fMRI data were processed with SPM software, version 12 (<ext-link ext-link-type="uri" xlink:href="http://www.fil.ion.ucl.ac.uk/spm">http://www.fil.ion.ucl.ac.uk/spm</ext-link>). To allow for imaging unit
stabilization and participant familiarization, the first ten scan volumes were
discarded for each participant. The remaining volumes were corrected for
slice-timing and motion artifacts. Translational and rotational head movements
were less than 2 mm and 2°, respectively, for all participants.</p>
<p>Covariates, including head motion, white matter signal, and cerebrospinal fluid
signal, were regressed out from the time series of every voxel. First, the
Friston 24-parameter model was used to regress out effects of head motion. Next,
data with a calculated frame-wise displacement &gt;0.5 for a specific volume
were regressed out. The datasets were filtered for band-pass frequencies in the
range of 0.01–0.08 Hz. Individual structural images were co-registered to a mean
functional image, and transformed structural images were co-registered to
Montreal Neurological Institute space via linear registration. Motion-corrected
functional volumes were spatially normalized to Montreal Neurological Institute
space based on parameters estimated during linear co-registration. Finally, the
functional images were re-sampled into 2-mm cubic voxels for further analysis.<sup><xref ref-type="bibr" rid="bibr17-0300060519884856">17</xref></sup></p>
</sec>
<sec id="sec6-0300060519884856">
<title>Calculation of gFCD</title>
<p>The gFCD of each voxel was calculated according to an in-house Linux script, as
previously described.<sup><xref ref-type="bibr" rid="bibr17-0300060519884856">17</xref></sup> Functional connectivity between voxels was evaluated with Pearson’s
linear correlation analysis, applying a threshold of R &gt; 0.6. The gFCD
calculations were limited to voxels within the cerebral grey matter mask. The
gFCD at any given voxel, x0, was calculated as the total number of functional
connections, k(x0), between x0 and all other voxels according to a growth
algorithm; this calculation was completed for all x0 voxels. Next, gFCD was
divided by the mean value of qualified voxels in the brain to increase the
normality of the distribution. The gFCD maps were spatially smoothed by a
6 × 6 × 6 mm<sup>3</sup> Gaussian kernel to minimize functional brain
anatomy differences between participants.<sup><xref ref-type="bibr" rid="bibr18-0300060519884856">18</xref>,<xref ref-type="bibr" rid="bibr19-0300060519884856">19</xref></sup> Changes in gFCD were
subjected to family-wise error correction.<sup><xref ref-type="bibr" rid="bibr20-0300060519884856">20</xref></sup></p>
</sec>
<sec id="sec7-0300060519884856">
<title>HTS</title>
<p>High throughput sequencing, which has enabled an important breakthrough in
schizophrenia research,<sup><xref ref-type="bibr" rid="bibr21-0300060519884856">21</xref></sup> was conducted with total RNA extracted from peripheral blood samples
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Total RNA was quantified in a NanoDrop ND-1000
machine and the integrity of each RNA sample was assessed by agarose gel
electrophoresis.</p>
</sec>
<sec id="sec8-0300060519884856">
<title>Microarray assay</title>
<p>Long non-coding (lnc) RNAs were collated from authoritative data sources
(principally Ref Seq, UCSC Known genes, and Ensembl) and RNA samples were
analysed on Arraystar human 8 × 60 K lncRNA microarrays (version 2.0) containing
33 045 lncRNAs and 30 215 mRNAs. Transcripts were identified with high-accuracy
specific exon or splice-junction probes. Sample labelling and array
hybridization were carried out according to the Agilent One-Color
Microarray-Based Gene Expression Analysis protocol (Agilent Technologies, Santa
Clara, CA, USA) with minor modifications. Subsequently, the arrays were washed,
fixed, and then scanned by an Agilent DNA Microarray Scanner (item No. G2505C).
The microarray experiments were performed by KangChen Bio-tech (Shanghai,
China).</p>
</sec>
<sec id="sec9-0300060519884856">
<title>Microarray data preprocessing</title>
<p>Microarray data analysis was performed in R and Bioconductor software packages.<sup><xref ref-type="bibr" rid="bibr22-0300060519884856">22</xref></sup> Raw expression data were log<sub>2</sub> transformed, background
corrected, and normalized by quantile normalization for both lncRNA and mRNA
datasets. A total of 21 250 lncRNAs and 21 654 mRNAs were carried over for
further analysis.</p>
</sec>
<sec id="sec10-0300060519884856">
<title>WGCNA</title>
<p>Weighted gene co-expression network analysis datasets for lncRNA and mRNA were
constructed in WGCNA R software.<sup><xref ref-type="bibr" rid="bibr23-0300060519884856">23</xref></sup> First, the most variable transcripts were selected, applying the
selection criterion of an absolute fold-change in expression of N 1.3 with a
<italic>P</italic> value &lt; 0.05 (two-sample <italic>t</italic>-test),<sup><xref ref-type="bibr" rid="bibr24-0300060519884856">24</xref></sup> which yielded the selection of 3 416 lncRNAs and 384 mRNAs for
construction of respective co-expression networks. Network construction was
performed with the block-wise module function in WGCNA R. A Pearson’s
correlation matrix was calculated for all possible RNA pairs and then
transformed into an adjacency matrix according to a power function, which
resulted in a weighted network. A dynamic tree cut algorithm was used to detect
groups of highly correlated genes. Modules were defined as tree branches and
colour-coded. Network preservation was assessed with the module preservation function.<sup><xref ref-type="bibr" rid="bibr25-0300060519884856">25</xref></sup> A preservation statistic Z summary N 2.0 indicated that the module in one
group was significantly preserved in another group.<sup><xref ref-type="bibr" rid="bibr26-0300060519884856">26</xref></sup> The expression profiles of each module were summarized by the module
eigengene, which was defined as the first principal component of the module. The
modules were subjected to multiple regressions with age and sex as covariates
using the linear model in the limma R package.<sup><xref ref-type="bibr" rid="bibr27-0300060519884856">27</xref></sup> In putative disease-related modules, RNAs that had high connectivity were
identified as hub RNAs.</p>
</sec>
<sec id="sec11-0300060519884856">
<title>Statistical analyses</title>
<p>Data are reported as mean ± SD. To define relationships between
disease-associated hub lncRNAs and mRNAs, CCA analysis was performed using the
CCP program in R.<sup><xref ref-type="bibr" rid="bibr28-0300060519884856">28</xref></sup>,<sup><xref ref-type="bibr" rid="bibr29-0300060519884856">29</xref></sup> Pearson’s correlation coefficient analysis was performed using SPSS
software, version 21.0 (IBM, Armonk, NY, USA) to identify relationships between
peak T-values of FC in the fMRI data and hub lncRNA and associated mRNA
expression quantities. <italic>P</italic> values &lt; 0.05 were considered to be
statistically significant.</p>
</sec>
</sec>
<sec id="sec12-0300060519884856" sec-type="results">
<title>Results</title>
<sec id="sec13-0300060519884856">
<title>Demographic and clinical profile of the study population</title>
<p>A total of five female patients were enrolled in the SCH-AVH group (mean age,
38.5 ± 4.5 years; mean educational level, 16.5 ± 2.5 years of schooling; mean
PANSS score, 71.3 ± 5.0; and mean AHRS score, 12.0 ± 2.5). The SCH-AVH group had
a mean illness duration of 36.0 ± 6.0 months and mean antipsychotic drug dosage
of 625.0 ± 125.5 mg/d (chlorpromazine equivalent dosage). Five female patients
were enrolled into the demographically-matched SCH-no AVH group (mean age,
38.0 ± 2.0 years; mean educational level, 16.0 ± 2.0 years; and mean PANSS
score, 69.5 ± 3.9). The SCH-no AVH group had a mean illness duration of
34.5 ± 5.6 months and mean antipsychotic drug dosage of 600.0 ± 130.5 mg/d
(chlorpromazine equivalent dosage). The two groups were statistically similar
(<italic>P</italic> &gt; 0.05) regarding the aforementioned clinical and
demographic variables.</p>
</sec>
<sec id="sec14-0300060519884856">
<title>Between-group differences in lncRNA and mRNA expression</title>
<p>Expression profiles for lncRNA and mRNA in the SCH-AVH and SCH-no AVH groups are
presented as fragments per kilobase of transcript per million mapped reads
(FPKMs; <xref ref-type="fig" rid="fig3-0300060519884856">Figure 3a</xref>).
Compared with the SCH-no AVH group, the SCH-AVH group displayed significantly
higher lncRNA and mRNA expression levels, in FPKMs, as well as greater
interactions between lncRNA MSTRG.96171.1 and 13 different mRNAs. A schematic of
this lncRNA-mRNA network is shown in <xref ref-type="fig" rid="fig3-0300060519884856">Figure 3b</xref>. LncRNA MSTRG.96171.1 was found
to interact with the following mRNAs: poly(ADP-ribose) polymerase family member
14 (PARP14); calcium-binding protein 39 (CAB39); bromodomain containing 2
(BRD2); toll-like receptor 6 (TLR6); adenosine A2A receptor (ADORA2A); slingshot
phosphatases 3 (SSH3); aspartic peptidase retroviral-like 1 (ASPRV1);
kyphoscoliosis peptidase (KY); ligand dependent nuclear receptor corepressor
(LCOR, formerly known as chromosome 10 open reading frame 12 or C10orf12);
ribosomal protein S18 (RPS18); GRINL1A complex locus 1 (GCOM1); thymosin beta 4
X-linked (TMSB4X); and transmembrane protein 63C (TMEM63C).</p>
<fig id="fig3-0300060519884856" orientation="portrait" position="float">
<label>Figure 3.</label>
<caption>
<p>Compared with the schizophrenia without AVHs (SCH-no AVH) group, patients
in the schizophrenia with AVHs (SCH-AVH) group had significantly
differentiated expression of components of a long noncoding (lnc)
RNA-mRNA network as well as functional connectivity (FC) alterations
affecting default mode network (DMN) structures. (a) LncRNA and mRNA
expression profiles, reported in fragments per kilobase of transcript
per million mapped reads (FPKMs) of the two groups. (b) LncRNA-mRNA
network that was found to have a differential expression profile between
the SCH-AVH and SCH-no AVH groups. Interactions among lncRNA
MSTRG.96171.1 (octagon node) and 13 defined mRNAs (diamond nodes) are
shown, including lncRNA-mRNA (wavy lines) and mRNA-mRNA (straight lines)
interactions. (c) Representative images showing FC alterations in
SCH-AVH participants (C1, coronal; C2, sagittal; and C3, axial images);
and (d) LncRNA-mRNA network-related FC alterations in SCH-AVH
participants (D1, coronal; D2, sagittal; and D3, axial images). PARP14,
poly(ADP-ribose) polymerase family member 14; CAB39, calcium-binding
protein 39; BRD2, bromodomain containing 2; TLR6, toll-like receptor 6;
ADORA2A, adenosine A2A receptor; SSH3,slingshot phosphatases 3; ASPRV1,
aspartic Peptidase Retroviral Like 1; KY, kyphoscoliosis Peptidase;
C10orf12, chromosome 10 open reading frame 12; RPS18, ribosomal Protein
S18; GCOM1, GRINL1A Complex Locus 1; TMSB4X, Thymosin Beta 4 X-Linked;
and TMEM63C, transmembrane protein 63C.</p>
</caption>
<graphic xlink:href="10.1177_0300060519884856-fig3"></graphic>
</fig>
</sec>
<sec id="sec15-0300060519884856">
<title>Between-group differences in FC</title>
<p>Significantly greater FC (represented by gFCD data) was observed within the DMN,
as well as in the right parietal lobe, left occipital lobe, and left temporal
lobe of participants in the SCH-AVH group compared with those in the SCH-no AVH
group. Representative images from SCH-AVH-group patients are shown in <xref ref-type="fig" rid="fig3-0300060519884856">Figure 3c</xref>.</p>
</sec>
<sec id="sec16-0300060519884856">
<title>Correlations between lncRNAs and peak gFCD T values within the DMN</title>
<p>Pearson analysis demonstrated significant correlation
(<italic>P</italic> &lt; 0.05) between peak gFCD T-values in major components of
the DMN and lncRNA MSTRG.96171.1 associated expression (representative images
from SCH-AVH-group patients are shown in <xref ref-type="fig" rid="fig3-0300060519884856">Figure 3d</xref>). Specifically, peak T-values
located in the posterior cingulate (<italic>r</italic> = 0.47) and in the
dorsal-medial prefrontal cortex (<italic>r</italic> = 0.53) correlated with
LncRNA MSTRG.96171.1 expression quantity.</p>
</sec>
</sec>
<sec id="sec17-0300060519884856" sec-type="discussion">
<title>Discussion</title>
<p>In the present study, HTS revealed a differentiated RNA network between patients with
schizophrenia who experience AVHs and those who do not (SCH-AVH group versus SCH-no
AVH group). An inter-group comparison of gFCD data revealed pathways with increased
FC within the DMN and within the right parietal lobe, left occipital lobe, and left
temporal lobe in the SCH-AVH group compared with values obtained for the SCH-no AVH
group. Furthermore, peak T values for FCs of three major structures in the DMN were
found to correlate with lncRNA MSTRG.96171.1 network expression.</p>
<p>Long noncoding RNAs have been reported to affect downstream gene expression, to
interfere with RNA splicing, to regulate the activity of proteins by binding them,
to act as structural components in nucleic acid-protein complexes, and to change the
cellular localization of proteins.<sup><xref ref-type="bibr" rid="bibr30-0300060519884856">30</xref><xref ref-type="bibr" rid="bibr31-0300060519884856"></xref><xref ref-type="bibr" rid="bibr32-0300060519884856"></xref><xref ref-type="bibr" rid="bibr33-0300060519884856"></xref><xref ref-type="bibr" rid="bibr34-0300060519884856"></xref><xref ref-type="bibr" rid="bibr35-0300060519884856"></xref><xref ref-type="bibr" rid="bibr36-0300060519884856"></xref><xref ref-type="bibr" rid="bibr37-0300060519884856"></xref>–<xref ref-type="bibr" rid="bibr38-0300060519884856">38</xref></sup> Hence, elucidating the
relationship between lncRNAs and schizophrenia can provide insights into the
pathological mechanisms of schizophrenia. A previous post-mortem study revealed a
schizophrenia-related mRNA network comprising lncRNAs and mRNAs in amygdala tissue.<sup><xref ref-type="bibr" rid="bibr39-0300060519884856">39</xref></sup> Though they were generated from a very small sample pilot study, the present
findings provide a new clue for investigating genetic and structural characteristics
of schizophrenia in the brains of living patients. Future large-sample cohort
studies may help to clarify RNA network influences on the pathological mechanisms of
schizophrenia.<sup><xref ref-type="bibr" rid="bibr31-0300060519884856">31</xref><xref ref-type="bibr" rid="bibr32-0300060519884856"></xref><xref ref-type="bibr" rid="bibr33-0300060519884856"></xref><xref ref-type="bibr" rid="bibr34-0300060519884856"></xref><xref ref-type="bibr" rid="bibr35-0300060519884856"></xref><xref ref-type="bibr" rid="bibr36-0300060519884856"></xref><xref ref-type="bibr" rid="bibr37-0300060519884856"></xref>–<xref ref-type="bibr" rid="bibr38-0300060519884856">38</xref></sup></p>
<p>Previously, the present authors found that FC strength alterations within the DMN (as
a unit) correlated with lncRNA-mRNA network alterations in schizophrenic patients
with AVHs.<sup><xref ref-type="bibr" rid="bibr40-0300060519884856">40</xref></sup> In the present pilot study, a different FC index was used, namely gFCD, which
reflects the number of voxels that are functionally connected to each other voxel in
the brain, and the relationship between gFCD alterations and expression of
components in a lncRNA-mRNA network was analysed. Importantly, because gFCD
represents the information communication ability of the whole brain,<sup><xref ref-type="bibr" rid="bibr41-0300060519884856">41</xref></sup> the presently observed gFCD differences between the SCH-AVH and SCH-no AVH
groups indicates that the characteristic of experiencing AVHs is associated with
differentiable information communication characteristics within the schizophrenic
population. Furthermore, this alteration in FC strength appears to occur
concomitantly with alterations in mRNA expression, providing evidence to support the
possibility that AVHs are related to alterations in both DMN FC strength,<sup><xref ref-type="bibr" rid="bibr40-0300060519884856">40</xref></sup> as well as to alterations in the numbers of functionally connected voxels
throughout the brain (current data) that can be related to abnormal expression
within a lncRNA-mRNA network.</p>
<sec id="sec18-0300060519884856">
<title>Clinical phenotyping bridges</title>
<p>Genomic features are endogenous characteristics whereas neuroimaging anomalies
may reflect neuropathological characteristics that underlie endophenotypes. It
can be inferred that genes influence, at least to some extent, the
neuropathological characteristics in patients with schizophrenia, including the
phenotypic expression of AVHs. Upon being verified and confirmed to be reliable,
phenotype-characteristic brain neuroimaging and gene expression markers may be
related to explicit clinical manifestations of AVHs and used to monitor patient
responses to therapy. In this context, a bridge is an observable marker that
reflects relationships among endogenous genetic characteristics, dominant
clinical features, and therapeutic outcomes. The identification of
characteristic markers that can be used as a bridge may be useful for clinical
phenotyping in advance of symptom onset or progression, and may further provide
an objective basis for early intervention before symptoms become prominent. A
summary of this proposed relationship between internal phenotype and
neuroimaging bridges is presented in a schematic diagram in <xref ref-type="fig" rid="fig4-0300060519884856">Figure 4</xref>.</p>
<fig id="fig4-0300060519884856" orientation="portrait" position="float">
<label>Figure 4.</label>
<caption>
<p>Cartoon showing use of bridges developed from genetic-neuroimaging
techniques to assess auditory verbal hallucination (AVH) subtypes, such
as AVHs in major depressive disorder (subtype A), AVHs in schizophrenia
(subtype B), and AVHs in healthy individuals (subtype C).</p>
</caption>
<graphic xlink:href="10.1177_0300060519884856-fig4"></graphic>
</fig>
<p>Given current technological limitations, there is not yet enough information to
establish a reliable bridge with which to fully explore the mechanisms that
mediate AVHs. For example, electrophysiological studies capture only broad-based
signals from the whole brain during AVHs, without providing any direct
quantitative information regarding levels or release of neurotransmitters in the
brain.<sup><xref ref-type="bibr" rid="bibr42-0300060519884856">42</xref><xref ref-type="bibr" rid="bibr43-0300060519884856"></xref><xref ref-type="bibr" rid="bibr44-0300060519884856"></xref><xref ref-type="bibr" rid="bibr45-0300060519884856"></xref>–<xref ref-type="bibr" rid="bibr46-0300060519884856">46</xref></sup> The present data are
suggestive of a tentative bridge with which to explore the mechanisms mediating
AVHs (<xref ref-type="fig" rid="fig4-0300060519884856">Figure 4</xref>). Future
technical advancements may lead to the recognition of a robust bridge, or
bridges, that can be used for in-depth studies of the AVH phenomenon.<sup><xref ref-type="bibr" rid="bibr47-0300060519884856">47</xref><xref ref-type="bibr" rid="bibr48-0300060519884856"></xref><xref ref-type="bibr" rid="bibr49-0300060519884856"></xref><xref ref-type="bibr" rid="bibr50-0300060519884856"></xref>–<xref ref-type="bibr" rid="bibr51-0300060519884856">51</xref></sup></p>
</sec>
<sec id="sec19-0300060519884856">
<title>Future outlook</title>
<p>Epidemiological evidence suggests that researchers should define a precise
classification scheme and develop targeted therapies for auditory hallucinations
in the contexts of different clinical conditions. Meanwhile, symptomatology
research has indicated that a qualitative diagnosis of patients experiencing
AVHs should be made early in differential diagnoses. Differentiable neuroimaging
presentations of different disorders presenting with AVHs suggests that specific
therapeutic targets for treating AVHs should be informed by particular
diagnoses. The authors expect that genetic studies will continue to reveal
genomic associations with AVHs that are specific to particular disorders.
Furthermore, genomic associations with AVHs should be explored in different
study populations, including in patients diagnosed with various neuropsychiatric
disorders. Machine learning approaches can be used to establish early
qualitative diagnostic and predictive indicators related to AVHs, including in
the context of particular disorders. The development of qualitative diagnostic
and therapeutic efficacy prediction models in patients with AVHs who have
various diagnoses may improve the accuracy and repeatability of prediction
models, and may, ultimately, facilitate the delivery of early, potentially
curative treatments.<sup><xref ref-type="bibr" rid="bibr7-0300060519884856">7</xref>,<xref ref-type="bibr" rid="bibr52-0300060519884856">52</xref><xref ref-type="bibr" rid="bibr53-0300060519884856"></xref><xref ref-type="bibr" rid="bibr54-0300060519884856"></xref><xref ref-type="bibr" rid="bibr55-0300060519884856"></xref><xref ref-type="bibr" rid="bibr56-0300060519884856"></xref><xref ref-type="bibr" rid="bibr57-0300060519884856"></xref><xref ref-type="bibr" rid="bibr58-0300060519884856"></xref><xref ref-type="bibr" rid="bibr59-0300060519884856"></xref>–<xref ref-type="bibr" rid="bibr60-0300060519884856">60</xref></sup></p>
<p>Data related to genomic characteristics, brain characterizations
(endophenotypes), clinical manifestations, and prognostic characteristics
(phenotypes) may be submitted to machine learning algorithms to establish
disease optimization classifiers that reveal characteristics that are specific
to particular diagnoses or common across neurological conditions accompanied by
AVHs. This approach may provide a basis for early AVH diagnosis and treatment
models in different diagnostic contexts based on imaging and genetic features.
Moreover, such data may enable the development of an objective evaluation system
to improve diagnosis and treatment efficiency. These developments should lead to
a reduction in AVH-induced harm. Empirical elucidation of highly specific and
stable imaging and genetic features of individuals who experience AVHs in
different neuropsychiatric disorders, and the identification of precise clinical
targets for potential early treatment, should stimulate discussion among basic
scientists and clinicians. Advancement of the study of auditory hallucinations
as a global problem should reduce the pitfalls of trial-and-error treatment
approaches.<sup><xref ref-type="bibr" rid="bibr56-0300060519884856">56</xref><xref ref-type="bibr" rid="bibr57-0300060519884856"></xref><xref ref-type="bibr" rid="bibr58-0300060519884856"></xref><xref ref-type="bibr" rid="bibr59-0300060519884856"></xref><xref ref-type="bibr" rid="bibr60-0300060519884856"></xref><xref ref-type="bibr" rid="bibr61-0300060519884856"></xref>–<xref ref-type="bibr" rid="bibr62-0300060519884856">62</xref></sup> A proposed prediction
model is shown in <xref ref-type="fig" rid="fig5-0300060519884856">Figure
5</xref>.</p>
<fig id="fig5-0300060519884856" orientation="portrait" position="float">
<label>Figure 5.</label>
<caption>
<p>Prediction model based on baseline genetic data, brain neuroimaging, and
clinical manifestations. The ideal predictive model would be able to
classify different auditory verbal hallucination (AVH) subtypes in the
early stages of illness. EEG, electroencephalogram.</p>
</caption>
<graphic xlink:href="10.1177_0300060519884856-fig5"></graphic>
</fig>
</sec>
</sec>
<sec id="sec20-0300060519884856" sec-type="conclusions">
<title>Conclusion</title>
<p>The present study revealed AVH-associated FC alterations among patients with
schizophrenia, within the DMN and within the right parietal lobe, left occipital
lobe, and left temporal lobe, as well as greater interactions of lncRNA
MSTRG.96171.1 with the expression of 13 different mRNAs. Because AVHs occur in
diverse populations, including in individuals with a diverse range of
neuropsychiatric disorders, as well as in healthy individuals, the present authors
propose exploring concomitant AVH-associated neuroimaging and genetic alterations
that are diagnosis-specific, in addition to those that are common across diagnoses.
The submission of such data to pattern recognition techniques may inform the
development of an objective index that could be used to support early differential
diagnosis and, ultimately, improve treatment planning for patients with AVHs. Other
scholars are invited to join in improving the quality of research in this field with
the ultimate goal of reducing AVH-associated distress.</p>
</sec>
</body>
<back>
<sec id="sec21-0300060519884856">
<title>Declaration of conflicting interest</title>
<p>The authors declare that there is no conflict of interest.</p>
</sec>
<sec id="sec22-0300060519884856">
<title>Funding</title>
<p>This work was supported by grants from the National Natural Science Foundation of
China (81871052 to CZ), the Key Projects of the Natural Science Foundation of
Tianjin, China (17JCZDJC35700 to CZ), the Tianjin Health Bureau Foundation (2014KR02
to CZ), the National Key Research and Development Program of China (2016YFC1307004
to YX), the Shanxi Science and Technology Innovation Training Team’s
Multidisciplinary Team for Cognitive Impairment (201705D131027 to YX), the Zhejiang
Public Welfare Fund Project (LGF18H090002 to DJ), the Tianjin Anding Hospital
Outstanding Award (300,000 CNY granted to CZ), and the key project of Wenzhou
Science and Technology Bureau (ZS2017011 to XL).</p>
</sec>
<sec>
<title>ORCID iD</title>
<p>Chuanjun Zhuo <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-3793-550X">https://orcid.org/0000-0002-3793-550X</ext-link></p>
</sec>
<ref-list content-type="numbered">
<title>References</title>
<ref id="bibr1-0300060519884856">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upthegrove</surname><given-names>R</given-names></name><name><surname>Broome</surname><given-names>MR</given-names></name><name><surname>Caldwell</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal>
<article-title>Understanding auditory
verbal hallucinations: a systematic review of current
evidence</article-title>. <source/>Acta Psychiatr Scand
<year>2016</year>; <volume>133</volume>:
<fpage>352</fpage>–<lpage>367</lpage>.<pub-id pub-id-type="pmid">26661730</pub-id></mixed-citation>
</ref>
<ref id="bibr2-0300060519884856">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kråkvik</surname><given-names>B</given-names></name><name><surname>Larøi</surname><given-names>F</given-names></name><name><surname>Kalhovde</surname><given-names>AM</given-names></name></person-group>, <etal>et al</etal>
<article-title>Prevalence of auditory
verbal hallucinations in a general population: a group comparison
study</article-title>. <source/>Scand J Psychol
<year>2015</year>; <volume>56</volume>:
<fpage>508</fpage>–<lpage>515</lpage>.<pub-id pub-id-type="pmid">26079977</pub-id></mixed-citation>
</ref>
<ref id="bibr3-0300060519884856">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernyhough</surname><given-names>C</given-names></name><name><surname>Waters</surname><given-names>F.</given-names></name></person-group>
<article-title>Special supplement introduction: hallucinations.</article-title>
<source/>Schizophr Bull
<year>2014</year>; <volume>40</volume>:
<fpage>S195</fpage>–<lpage>S197</lpage>.<pub-id pub-id-type="pmid">24936079</pub-id></mixed-citation>
</ref>
<ref id="bibr4-0300060519884856">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>F</given-names></name><name><surname>Woods</surname><given-names>A</given-names></name><name><surname>Fernyhough</surname><given-names>C.</given-names></name></person-group>
<article-title>Report on the 2nd International Consortium on Hallucination
Research: evolving directions and top-10 “hot spots” in hallucination
research.</article-title>
<source/>Schizophr Bull
<year>2014</year>; <volume>40</volume>:
<fpage>24</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">24282321</pub-id></mixed-citation>
</ref>
<ref id="bibr5-0300060519884856">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>N</given-names></name><name><surname>Rossell</surname><given-names>SL</given-names></name><name><surname>Waters</surname><given-names>F.</given-names></name></person-group>
<article-title>The changing face of hallucination research: the International
Consortium on Hallucination Research (ICHR) 2015 meeting
report</article-title>. <source/>Schizophr Bull
<year>2016</year>; <volume>42</volume>:
<fpage>891</fpage>–<lpage>895</lpage>.<pub-id pub-id-type="pmid">26675294</pub-id></mixed-citation>
</ref>
<ref id="bibr6-0300060519884856">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardri</surname><given-names>R</given-names></name><name><surname>Larøi</surname><given-names>F</given-names></name><name><surname>Waters</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>
<article-title>Hallucination research: into
the future, and beyond</article-title>. <source/>Schizophr Bull
<year>2019</year>; <volume>45</volume>:
<fpage>S1</fpage>–<lpage>S4</lpage>.<pub-id pub-id-type="pmid">30715538</pub-id></mixed-citation>
</ref>
<ref id="bibr7-0300060519884856">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humpston</surname><given-names>CS</given-names></name><name><surname>Adams</surname><given-names>RA</given-names></name><name><surname>Benrimoh</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>From computation to the
first-person: auditory-verbal hallucinations and delusions of thought
interference in schizophrenia-spectrum psychoses.</article-title>
<source/>Schizophr Bull
<year>2019</year>; <volume>45</volume>:
<fpage>S56</fpage>–<lpage>S66</lpage>.<pub-id pub-id-type="pmid">30715542</pub-id></mixed-citation>
</ref>
<ref id="bibr8-0300060519884856">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hugdahl</surname><given-names>K.</given-names></name></person-group>
<article-title>Auditory hallucinations: a review of the ERC “VOICE”
project.</article-title>
<source/>World J Psychiatry
<year>2015</year>; <volume>5</volume>:
<fpage>193</fpage>–<lpage>209</lpage>.<pub-id pub-id-type="pmid">26110121</pub-id></mixed-citation>
</ref>
<ref id="bibr9-0300060519884856">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Understanding auditory
verbal hallucinations in healthy individuals and individuals with
psychiatric disorders.</article-title>
<source/>Psychiatry Res
<year>2019</year>; <volume>274</volume>:
<fpage>213</fpage>–<lpage>219</lpage>.<pub-id pub-id-type="pmid">30807972</pub-id></mixed-citation>
</ref>
<ref id="bibr10-0300060519884856">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Auditory verbal
hallucination and the auditory network: from molecules to
connectivity.</article-title>
<source/>Neuroscience
<year>2019</year>; <volume>410</volume>:
<fpage>59</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">31082536</pub-id></mixed-citation>
</ref>
<ref id="bibr11-0300060519884856">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>SR</given-names></name><name><surname>Fiszbein</surname><given-names>A</given-names></name><name><surname>Opler</surname><given-names>LA.</given-names></name></person-group>
<article-title>The positive and negative syndrome scale (PANSS) for
schizophrenia</article-title>. <source/>Schizophr Bull
<year>1987</year>; <volume>13</volume>:
<fpage>261</fpage>–<lpage>276</lpage>.<pub-id pub-id-type="pmid">3616518</pub-id></mixed-citation>
</ref>
<ref id="bibr12-0300060519884856">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>SW.</given-names></name></person-group>
<article-title>Chlorpromazine equivalent doses for the newer atypical
antipsychotics.</article-title>
<source/>J Clin Psychiatry
<year>2003</year>; <volume>64</volume>:
<fpage>663</fpage>–<lpage>667</lpage>.<pub-id pub-id-type="pmid">12823080</pub-id></mixed-citation>
</ref>
<ref id="bibr13-0300060519884856">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddock</surname><given-names>G</given-names></name><name><surname>McCarron</surname><given-names>J</given-names></name><name><surname>Tarrier</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal>
<article-title>Scales to measure dimensions
of hallucinations and delusions: the psychotic symptom rating scales
(PSYRATS).</article-title>
<source/>Psychol Med
<year>1999</year>; <volume>29</volume>:
<fpage>879</fpage>–<lpage>889</lpage>.<pub-id pub-id-type="pmid">10473315</pub-id></mixed-citation>
</ref>
<ref id="bibr14-0300060519884856">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dragovic</surname><given-names>M</given-names></name><name><surname>Hammond</surname><given-names>G.</given-names></name></person-group>
<article-title>A classification of handedness using the Annett Hand Preference
Questionnaire.</article-title>
<source/>Br J Psychol
<year>2007</year>; <volume>98</volume>:
<fpage>375</fpage>–<lpage>387</lpage>.<pub-id pub-id-type="pmid">17705937</pub-id></mixed-citation>
</ref>
<ref id="bibr15-0300060519884856">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>The effect of dopamine
antagonist treatment on auditory verbal hallucinations in healthy
individuals is clearly influenced by <italic>COMT</italic> genotype and
accompanied by corresponding brain structural and functional alterations: an
artificially controlled pilot study</article-title>. <source/>Front
Genet
<year>2019</year>; <volume>10</volume>: <issue>92</issue>.</mixed-citation>
</ref>
<ref id="bibr16-0300060519884856">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Different spatial patterns
of brain atrophy and global functional connectivity impairments in major
depressive disorder.</article-title>
<source/>Brain Imaging Behav
<year>2017</year>; <volume>11</volume>:
<fpage>1678</fpage>–<lpage>1689</lpage>.<pub-id pub-id-type="pmid">27766588</pub-id></mixed-citation>
</ref>
<ref id="bibr17-0300060519884856">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>
<article-title>Functional brain alterations
in auditory hallucination subtypes in individuals with auditory
hallucinations without the diagnosis of specific neurological diseases and
mental disorders at the current stage.</article-title>
<source/>Brain Behav
<year>2020</year>; <volume>10</volume>: <fpage>e01487</fpage>.<pub-id pub-id-type="pmid">31782626</pub-id></mixed-citation>
</ref>
<ref id="bibr18-0300060519884856">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Common and distinct global
functional connectivity density alterations in drug-naïve patients with
first-episode major depressive disorder with and without auditory verbal
hallucination.</article-title>
<source/>Prog Neuropsychopharmacol Biol Psychiatry
<year>2020</year>; <volume>96</volume>: <fpage>109738</fpage>.<pub-id pub-id-type="pmid">31442554</pub-id></mixed-citation>
</ref>
<ref id="bibr19-0300060519884856">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Brain structural and
functional dissociated patterns in schizophrenia.</article-title>
<source/>BMC Psychiatry
<year>2017</year>; <volume>17</volume>: <fpage>45</fpage>.<pub-id pub-id-type="pmid">28143464</pub-id></mixed-citation>
</ref>
<ref id="bibr20-0300060519884856">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandekar</surname><given-names>SN</given-names></name><name><surname>Satterthwaite</surname><given-names>TD</given-names></name><name><surname>Rosen</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>Faster family-wise error
control for neuroimaging with a parametric bootstrap.</article-title>
<source/>Biostatistics
<year>2018</year>; <volume>19</volume>:
<fpage>497</fpage>–<lpage>513</lpage>.<pub-id pub-id-type="pmid">29059370</pub-id></mixed-citation>
</ref>
<ref id="bibr21-0300060519884856">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yolken</surname><given-names>RH</given-names></name><name><surname>Severance</surname><given-names>EG</given-names></name><name><surname>Sabunciyan</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Metagenomic sequencing
indicates that the oropharyngeal phageome of individuals with schizophrenia
differs from that of controls.</article-title>
<source/>Schizophr Bull
<year>2015</year>; <volume>41</volume>:
<fpage>1153</fpage>–<lpage>1161</lpage>.<pub-id pub-id-type="pmid">25666826</pub-id></mixed-citation>
</ref>
<ref id="bibr22-0300060519884856">
<label>22</label>
<mixed-citation publication-type="other"><collab>The R Core Team. R: a language and
environment for statistical computing. R Foundation for Statistical
Computing 3-900051-07-0, Vienna, Austria</collab> (2012).</mixed-citation>
</ref>
<ref id="bibr23-0300060519884856">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langfelder</surname><given-names>P</given-names></name><name><surname>Horvath</surname><given-names>S.</given-names></name></person-group>
<article-title>WGCNA: an R package for weighted correlation network
analysis.</article-title>
<source/>BMC Bioinformatics
<year>2008</year>; <volume>9</volume>: <fpage>559</fpage>.<pub-id pub-id-type="pmid">19114008</pub-id></mixed-citation>
</ref>
<ref id="bibr24-0300060519884856">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Horvath</surname><given-names>S.</given-names></name></person-group>
<article-title>A general framework for weighted gene co-expression network
analysis</article-title>. <source/>Stat Appl Genet Mol Biol
<year>2005</year>; <volume>4</volume>:
<fpage>Article17</fpage>.<pub-id pub-id-type="pmid">16646834</pub-id></mixed-citation>
</ref>
<ref id="bibr25-0300060519884856">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langfelder</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Oldham</surname><given-names>MC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Is my network module
preserved and reproducible?</article-title>
<source/>PLoS Comput Biol
<year>2011</year>; <volume>7</volume>: <fpage>e1001057</fpage>.<pub-id pub-id-type="pmid">21283776</pub-id></mixed-citation>
</ref>
<ref id="bibr26-0300060519884856">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossignol</surname><given-names>DA</given-names></name><name><surname>Frye</surname><given-names>RE.</given-names></name></person-group>
<article-title>Mitochondrial dysfunction in autism spectrum disorders: a
systematic review and meta-analysis.</article-title>
<source/>Mol Psychiatry
<year>2012</year>; <volume>17</volume>:
<fpage>290</fpage>–<lpage>314</lpage>.<pub-id pub-id-type="pmid">21263444</pub-id></mixed-citation>
</ref>
<ref id="bibr27-0300060519884856">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>GK.</given-names></name></person-group>
<article-title>Linear models and empirical Bayes methods for assessing
differential expression in microarray experiments</article-title>.
<source/>Stat Appl Genet Mol Biol
<year>2004</year>; <volume>3</volume>: <fpage>Article3</fpage>.<pub-id pub-id-type="pmid">16646809</pub-id></mixed-citation>
</ref>
<ref id="bibr28-0300060519884856">
<label>28</label>
<mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Menzel</surname><given-names>U. CCP</given-names></name></person-group>: significance tests for canonical correlation analysis (CCA).
<italic>R package version 1.1,</italic>
<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=CCP">https://CRAN.R-project.org/package=CCP</ext-link>
(<year>2012</year>).</mixed-citation>
</ref>
<ref id="bibr29-0300060519884856">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Canonical correlation
analysis for RNA-seq co-expression networks.</article-title>
<source/>Nucleic Acids Res
<year>2013</year>; <volume>41</volume>: <fpage>e95</fpage>.<pub-id pub-id-type="pmid">23460206</pub-id></mixed-citation>
</ref>
<ref id="bibr30-0300060519884856">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name></person-group>, <etal>et al</etal>
<article-title>High-speed recording of
neural spikes in awake mice and flies with a fluorescent voltage
sensor.</article-title>
<source/>Science
<year>2015</year>; <volume>350</volume>:
<fpage>1361</fpage>–<lpage>1366</lpage>.<pub-id pub-id-type="pmid">26586188</pub-id></mixed-citation>
</ref>
<ref id="bibr31-0300060519884856">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>G</given-names></name><name><surname>Briggs</surname><given-names>JA</given-names></name><name><surname>Vanichkina</surname><given-names>DP</given-names></name></person-group>, <etal>et al</etal>
<article-title>The long non-coding RNA
Gomafu is acutely regulated in response to neuronal activation and involved
in schizophrenia-associated alternative splicing.</article-title>
<source/>Mol Psychiatry
<year>2014</year>; <volume>19</volume>:
<fpage>486</fpage>–<lpage>494</lpage>.<pub-id pub-id-type="pmid">23628989</pub-id></mixed-citation>
</ref>
<ref id="bibr32-0300060519884856">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>JY</given-names></name></person-group>, <etal>et al</etal>
<article-title>Gene expression profiling by
mRNA sequencing reveals increased expression of immune/inflammation-related
genes in the hippocampus of individuals with schizophrenia.</article-title>
<source/>Transl Psychiatry
<year>2013</year>; <volume>3</volume>: <fpage>e321</fpage>.<pub-id pub-id-type="pmid">24169640</pub-id></mixed-citation>
</ref>
<ref id="bibr33-0300060519884856">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glatt</surname><given-names>SJ</given-names></name><name><surname>Everall</surname><given-names>IP</given-names></name><name><surname>Kremen</surname><given-names>WS</given-names></name></person-group>, <etal>et al</etal>
<article-title>Comparative gene expression
analysis of blood and brain provides concurrent validation of SELENBP1
up-regulation in schizophrenia.</article-title>
<source/>Proc Natl Acad Sci USA
<year>2005</year>; <volume>102</volume>:
<fpage>15533</fpage>–<lpage>15538</lpage>.<pub-id pub-id-type="pmid">16223876</pub-id></mixed-citation>
</ref>
<ref id="bibr34-0300060519884856">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name><name><surname>Hahn</surname><given-names>CG</given-names></name></person-group>, <etal>et al</etal>
<article-title>Non-coding RNA dysregulation
in the amygdala region of schizophrenia patients contributes to the
pathogenesis of the disease.</article-title>
<source/>Transl Psychiatry
<year>2018</year>; <volume>8</volume>: <fpage>44</fpage>.<pub-id pub-id-type="pmid">29391398</pub-id></mixed-citation>
</ref>
<ref id="bibr35-0300060519884856">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>XS</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>A network analysis of
epigenetic and transcriptional regulation in a neurodevelopmental rat model
of schizophrenia with implications for translational
research.</article-title>
<source/>Schizophr Bull
<year>2020</year>; <volume>46</volume>:
<fpage>612</fpage>–<lpage>622</lpage>.<pub-id pub-id-type="pmid">31738422</pub-id></mixed-citation>
</ref>
<ref id="bibr36-0300060519884856">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oswald</surname><given-names>F</given-names></name><name><surname>Klöble</surname><given-names>P</given-names></name><name><surname>Ruland</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal>
<article-title>The FOXP2-driven network in
developmental disorders and neurodegeneration</article-title>. <source/>Front
Cell Neurosci
<year>2017</year>; <volume>11</volume>: <issue>212</issue>.</mixed-citation>
</ref>
<ref id="bibr37-0300060519884856">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>HQ</given-names></name><name><surname>Catts</surname><given-names>VS</given-names></name><name><surname>Webster</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Increased macrophages and
changed brain endothelial cell gene expression in the frontal cortex of
people with schizophrenia displaying inflammation.</article-title>
<source/>Mol Psychiatry
<year>2020</year>; <volume>25</volume>:
<fpage>761</fpage>–<lpage>775</lpage>.<pub-id pub-id-type="pmid">30214039</pub-id></mixed-citation>
</ref>
<ref id="bibr38-0300060519884856">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volk</surname><given-names>DW</given-names></name><name><surname>Moroco</surname><given-names>AE</given-names></name><name><surname>Roman</surname><given-names>KM</given-names></name></person-group>, <etal>et al</etal>
<article-title>The role of the nuclear
factor-κB transcriptional complex in cortical immune activation in
schizophrenia.</article-title>
<source/>Biol Psychiatry
<year>2019</year>; <volume>85</volume>:
<fpage>25</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">30082065</pub-id></mixed-citation>
</ref>
<ref id="bibr39-0300060519884856">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Chang</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>The long noncoding RNA
landscape in amygdala tissues from schizophrenia patients.</article-title>
<source/>EBioMedicine
<year>2018</year>; <volume>34</volume>:
<fpage>171</fpage>–<lpage>181</lpage>.<pub-id pub-id-type="pmid">30077719</pub-id></mixed-citation>
</ref>
<ref id="bibr40-0300060519884856">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Association of a novel long
non-coding RNA-mRNAs network with default mode network hyper-connectivity in
hallucinative schizophrenia</article-title>. <source/>Ann Clin Case
Rep
<year>2019</year>; <volume>4</volume>: <fpage>1657</fpage>.</mixed-citation>
</ref>
<ref id="bibr41-0300060519884856">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>W</given-names></name></person-group>, <etal>et al</etal>
<article-title>Brain functional
connectivity density and individual fluid reasoning capacity in healthy
young adults</article-title>. <source/>Neuroreport
<year>2015</year>; <volume>26</volume>:
<fpage>17</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">25426825</pub-id></mixed-citation>
</ref>
<ref id="bibr42-0300060519884856">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>P</given-names></name><name><surname>Ahrens</surname><given-names>MB.</given-names></name></person-group>
<article-title>Visualizing whole-brain activity and development at the
single-cell level using light-sheet microscopy.</article-title>
<source/>Neuron
<year>2015</year>; <volume>85</volume>:
<fpage>462</fpage>–<lpage>483</lpage>.<pub-id pub-id-type="pmid">25654253</pub-id></mixed-citation>
</ref>
<ref id="bibr43-0300060519884856">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Gong</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>Micro-optical sectioning
tomography to obtain a high-resolution atlas of the mouse
brain.</article-title>
<source/>Science
<year>2010</year>; <volume>330</volume>:
<fpage>1404</fpage>–<lpage>1408</lpage>.<pub-id pub-id-type="pmid">21051596</pub-id></mixed-citation>
</ref>
<ref id="bibr44-0300060519884856">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>NeuroGPS-Tree: automatic
reconstruction of large-scale neuronal populations with dense
neurites.</article-title>
<source/>Nat Methods
<year>2016</year>; <volume>13</volume>:
<fpage>51</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">26595210</pub-id></mixed-citation>
</ref>
<ref id="bibr45-0300060519884856">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowland</surname><given-names>CE</given-names></name><name><surname>Susumu</surname><given-names>K</given-names></name><name><surname>Stewart</surname><given-names>MH</given-names></name></person-group>, <etal>et al</etal>
<article-title>Electric field modulation of
semiconductor quantum dot photoluminescence: insights into the design of
robust voltage-sensitive cellular imaging probes.</article-title>
<source/>Nano Lett
<year>2015</year>; <volume>15</volume>:
<fpage>6848</fpage>–<lpage>6854</lpage>.<pub-id pub-id-type="pmid">26414396</pub-id></mixed-citation>
</ref>
<ref id="bibr46-0300060519884856">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal>
<article-title>Syringe-injectable
electronics.</article-title>
<source/>Nat Nanotechnol
<year>2015</year>; <volume>10</volume>:
<fpage>629</fpage>–<lpage>636</lpage>.<pub-id pub-id-type="pmid">26053995</pub-id></mixed-citation>
</ref>
<ref id="bibr47-0300060519884856">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohlken</surname><given-names>MM</given-names></name><name><surname>Hugdahl</surname><given-names>K</given-names></name><name><surname>Sommer</surname><given-names>IEC.</given-names></name></person-group>
<article-title>Auditory verbal hallucinations: neuroimaging and
treatment.</article-title>
<source/>Psychol Med
<year>2017</year>; <volume>47</volume>:
<fpage>199</fpage>–<lpage>208</lpage>.<pub-id pub-id-type="pmid">27383425</pub-id></mixed-citation>
</ref>
<ref id="bibr48-0300060519884856">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blom</surname><given-names>JD.</given-names></name></person-group>
<article-title>Auditory hallucinations.</article-title>
<source/>Handb Clin Neurol
<year>2015</year>; <volume>129</volume>:
<fpage>433</fpage>–<lpage>455</lpage>.<pub-id pub-id-type="pmid">25726283</pub-id></mixed-citation>
</ref>
<ref id="bibr49-0300060519884856">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Ding</surname><given-names>Z</given-names></name></person-group>, <etal>et al</etal>
<article-title>Machine learning identifies
unaffected first-degree relatives with functional network patterns and
cognitive impairment similar to those of schizophrenia
patients.</article-title>
<source/>Hum Brain Mapp
<year>2019</year>; <volume>40</volume>:
<fpage>3930</fpage>–<lpage>3939</lpage>.<pub-id pub-id-type="pmid">31148311</pub-id></mixed-citation>
</ref>
<ref id="bibr50-0300060519884856">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ffytche</surname><given-names>DH</given-names></name><name><surname>Wible</surname><given-names>CG.</given-names></name></person-group>
<article-title>From tones in tinnitus to sensed social interaction in
schizophrenia: how understanding cortical organization can inform the study
of hallucinations and psychosis.</article-title>
<source/>Schizophr Bull
<year>2014</year>; <volume>40</volume>:
<fpage>S305</fpage>–<lpage>S316</lpage>.<pub-id pub-id-type="pmid">24936089</pub-id></mixed-citation>
</ref>
<ref id="bibr51-0300060519884856">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Leede-Smith</surname><given-names>S</given-names></name><name><surname>Barkus</surname><given-names>E.</given-names></name></person-group>
<article-title>A comprehensive review of auditory verbal hallucinations:
lifetime prevalence, correlates and mechanisms in healthy and clinical
individuals.</article-title>
<source/>Front Hum Neurosci
<year>2013</year>; <volume>7</volume>: <fpage>367</fpage>.<pub-id pub-id-type="pmid">23882203</pub-id></mixed-citation>
</ref>
<ref id="bibr52-0300060519884856">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Leede-Smith</surname><given-names>S</given-names></name><name><surname>Roodenrys</surname><given-names>S</given-names></name><name><surname>Horsley</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neurological soft signs:
effects of trait schizotypy, psychological distress and auditory
hallucination predisposition.</article-title>
<source/>Schizophr Res Cogn
<year>2016</year>; <volume>7</volume>:
<fpage>1</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">28740822</pub-id></mixed-citation>
</ref>
<ref id="bibr53-0300060519884856">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavigne</surname><given-names>KM</given-names></name><name><surname>Woodward</surname><given-names>TS.</given-names></name></person-group>
<article-title>Hallucination- and speech-specific hypercoupling in
frontotemporal auditory and language networks in schizophrenia using
combined task-based fMRI data: an fBIRN study.</article-title>
<source/>Hum Brain Mapp
<year>2018</year>; <volume>39</volume>:
<fpage>1582</fpage>–<lpage>1595</lpage>.<pub-id pub-id-type="pmid">29271110</pub-id></mixed-citation>
</ref>
<ref id="bibr54-0300060519884856">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alderson-Day</surname><given-names>B</given-names></name><name><surname>Smailes</surname><given-names>D</given-names></name><name><surname>Moffatt</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>
<article-title>Intentional inhibition but
not source memory is related to hallucination-proneness and intrusive
thoughts in a university sample.</article-title>
<source/>Cortex
<year>2019</year>; <volume>113</volume>:
<fpage>267</fpage>–<lpage>278</lpage>.<pub-id pub-id-type="pmid">30716609</pub-id></mixed-citation>
</ref>
<ref id="bibr55-0300060519884856">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Looijestijn</surname><given-names>J</given-names></name><name><surname>Blom</surname><given-names>JD</given-names></name><name><surname>Hoek</surname><given-names>HW</given-names></name></person-group>, <etal>et al</etal>
<article-title>Draining the pond and
catching the fish: uncovering the ecosystem of auditory verbal
hallucinations.</article-title>
<source/>Neuroimage Clin
<year>2018</year>; <volume>20</volume>:
<fpage>830</fpage>–<lpage>843</lpage>.<pub-id pub-id-type="pmid">30273840</pub-id></mixed-citation>
</ref>
<ref id="bibr56-0300060519884856">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiebes</surname><given-names>S</given-names></name><name><surname>Steinmann</surname><given-names>S</given-names></name><name><surname>Curic</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alterations in
interhemispheric gamma-band connectivity are related to the emergence of
auditory verbal hallucinations in healthy subjects during NMDA-receptor
blockade.</article-title>
<source/>Neuropsychopharmacology
<year>2018</year>; <volume>43</volume>:
<fpage>1608</fpage>–<lpage>1615</lpage>.<pub-id pub-id-type="pmid">29453445</pub-id></mixed-citation>
</ref>
<ref id="bibr57-0300060519884856">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddi</surname><given-names>S</given-names></name><name><surname>Ochoa</surname><given-names>S</given-names></name><name><surname>Laroi</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal>
<article-title>A cross-national
investigation of hallucination-like experiences in 10 countries: the
E-CLECTIC study.</article-title>
<source/>Schizophr Bull
<year>2019</year>; <volume>45</volume>:
<fpage>S43</fpage>–<lpage>S55</lpage>.<pub-id pub-id-type="pmid">30715543</pub-id></mixed-citation>
</ref>
<ref id="bibr58-0300060519884856">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horga</surname><given-names>G</given-names></name><name><surname>Abi-Dargham</surname><given-names>A.</given-names></name></person-group>
<article-title>An integrative framework for perceptual disturbances in
psychosis</article-title>. <source/>Nat Rev Neurosci
<year>2019</year>; <volume>20</volume>:
<fpage>763</fpage>–<lpage>778</lpage>.<pub-id pub-id-type="pmid">31712782</pub-id></mixed-citation>
</ref>
<ref id="bibr59-0300060519884856">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maijer</surname><given-names>K</given-names></name><name><surname>Hayward</surname><given-names>M</given-names></name><name><surname>Fernyhough</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Hallucinations in children
and adolescents: an updated review and practical recommendations for
clinicians.</article-title>
<source/>Schizophr Bull
<year>2019</year>; <volume>45</volume>:
<fpage>S5</fpage>–<lpage>S23</lpage>.<pub-id pub-id-type="pmid">30715540</pub-id></mixed-citation>
</ref>
<ref id="bibr60-0300060519884856">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrison</surname><given-names>JR</given-names></name><name><surname>Fernyhough</surname><given-names>C</given-names></name><name><surname>McCarthy-Jones</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Paracingulate sulcus
morphology and hallucinations in clinical and nonclinical
groups.</article-title>
<source/>Schizophr Bull
<year>2019</year>; <volume>45</volume>:
<fpage>733</fpage>–<lpage>741</lpage>.<pub-id pub-id-type="pmid">30380115</pub-id></mixed-citation>
</ref>
<ref id="bibr61-0300060519884856">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheinost</surname><given-names>D</given-names></name><name><surname>Noble</surname><given-names>S</given-names></name><name><surname>Horien</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>Ten simple rules for
predictive modeling of individual differences in
neuroimaging</article-title>
<source/>Neuroimage
<year>2019</year>; <volume>193</volume>:
<fpage>35</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">30831310</pub-id></mixed-citation>
</ref>
<ref id="bibr62-0300060519884856">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>S</given-names></name><name><surname>Westmoreland</surname><given-names>JJ</given-names></name><name><surname>Bayazitov</surname><given-names>IT</given-names></name></person-group>, <etal>et al</etal>
<article-title>Specific disruption of
thalamic inputs to the auditory cortex in schizophrenia
models.</article-title>
<source/>Science
<year>2014</year>; <volume>344</volume>:
<fpage>1178</fpage>–<lpage>1182</lpage>.<pub-id pub-id-type="pmid">24904170</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>